Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

Despite their effectiveness, GLP-1 drugs remain costly and are only covered by Medicaid in 13 states, raising concerns about equitable access.

GLP-1 receptor agonists, such as Wegovy and Ozempic, have surged in popularity, with usage in the U.S. rising from 190,000 to 1.8 million monthly claims since 2014.
The drugs show promise in reducing obesity-related conditions but are accompanied by side effects and high costs, with prices exceeding $1,000 monthly for uninsured patients.
Medicaid coverage for GLP-1 drugs is limited to 13 states, with others citing cost as a barrier despite potential long-term savings from reduced chronic disease rates.
Demographic disparities are evident, as wealthier and white individuals are more likely to access these drugs, while minorities and lower-income groups face greater barriers.
Analysts predict significant societal impacts from widespread GLP-1 use, including reduced obesity rates, economic benefits, and challenges for industries like food and transportation.